S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT

Recruiting at51 trial locations

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: SWOG Cancer Research Network

No Placebo Group

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

RATIONALE: Learning about the long-term effects of chemoprevention drugs, such as finasteride, in patients with prostate cancer may help doctors plan better treatment and follow-up care. PURPOSE: This clinical trial is following patients who were diagnosed with prostate cancer while undergoing treatment with either finasteride or a placebo on the Prostate Cancer Prevention Trial (PCPT).

Research Team

Ian M. Thompson, MD

Principal Investigator

The University of Texas Health Science Center at San Antonio

Scott M. Lippman, MD, FACP

Principal Investigator

M.D. Anderson Cancer Center

E. David Crawford, MD

Principal Investigator

University of Colorado, Denver

Eligibility Criteria

Inclusion Criteria

Randomized on PCPT

Diagnosed with prostate cancer on or before December 31, 2003

Diagnosed by either study site or central pathology review

Treatment Details

Interventions

• Finasteride (5-alpha Reductase Inhibitor)

Participant Groups

Group I: Long Term Follow-Up Experimental Treatment 1 Intervention

Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)

Who Is Running the Clinical Trial?

SWOG Cancer Research Network

Lead Sponsor

Trials

403

Recruited

267,000+

Dr. Charles D. Blanke

SWOG Cancer Research Network

Chief Executive Officer since 2012

MD from Oregon Health & Science University

Dr. Dawn Hershman

SWOG Cancer Research Network

Chief Medical Officer since 2020

MD from Columbia University

Southwest Oncology Group

Lead Sponsor

Trials

389

Recruited

260,000+

Dr. Lyudmila Bazhenova

Southwest Oncology Group

Chief Medical Officer since 2021

MD from University of California, San Diego

Dr. Richard Schilsky

Southwest Oncology Group

Chief Executive Officer since 2013

MD from University of California, San Diego

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School